Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 2 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1 Head & Neck 1

Conditions

Neoplasm Metastasis 3 Breast Neoplasms 2 Urologic Neoplasms 1 Urologic Diseases 1 Urinary Bladder Neoplasms 1 Urinary Bladder Diseases 1 Triple Negative Breast Neoplasms 1 Stomatitis 1 Rectal Neoplasms 1 Pain, Postoperative 1 Non-Muscle Invasive Bladder Neoplasms 1 Neoplasms 1 Mucositis 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Fibroblast Growth Factor 7 9 avasopasem manganese 4 Cisplatin 4 Radiotherapy, Intensity-Modulated 3 Injections 3 golotimod 2 Saline Solution 2 Radiotherapy 2 RRx-001 2 Mouthwashes 2 Low-Level Light Therapy 2 FGF20 protein, human 2 Drug Therapy 2 Benzydamine 2 meclocycline 1 hydrated silica gel-based toothpaste 1 dusquetide 1 cobiprostone 1 clazakizumab 1 brilacidin 1 amlexanox 1 aluminum hydroxide, magnesium hydroxide, drug combination 1 Xylitol 1 Whole-Body Irradiation 1 Water 1 Transplantation Conditioning 1 Standard of Care 1 Radiation 1 Prednisolone 1 Niacinamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Stomatitis × Water × Clear all

NCT02324335 2019-01-16

Brilacidin

Innovation Pharmaceuticals, Inc.

Phase 2 Completed

61 enrolled 12 charts

Head & NeckOther

Head and Neck Neoplasms, Stomatitis, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡